Chinese Biopharma Stocks Rise as US Signals Openness to Drug Licensing Deals
Shares in Chinese biopharmaceutical stocks rose on Monday, driven by a report that the U.S. may allow most drug licensing deals with Chinese companies to continue. Innovent Biologics and Akeso saw their shares rise by 7% and 8%, respectively. The potential shift in policy comes amid ongoing trade tensions between China and the United States but suggests some easing of restrictions on pharmaceutical collaborations. This development has been welcomed as a positive sign for cross-border cooperation, particularly within the biopharma sector where Chinese firms have increasingly partnered with U.S.-based companies to develop and commercialize drugs. The market reaction indicates investor optimism that continued licensing agreements could support growth in China's life sciences industry while maintaining access to key markets.
Tickers: $IVBIY